Professional
Added to YB: 2024-05-15
Pitch date: 2024-05-09
RPRX [bullish]
Royalty Pharma plc
+126.13%
current return
Author Info
No bio for this author
Company Info
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States.
Market Cap
$25.8B
Pitch Price
$26.79
Price Target
52.00 (-16%)
Dividend
1.62%
EV/EBITDA
23.01
P/E
31.09
EV/Sales
14.55
Sector
Pharmaceuticals
Category
growth
Royalty Pharma Earnings: Expansion of Development Stage Pipeline Reinforces Growth Prospects
RPRX: Q1 results in line, $52 FV unch. Vanzacaftor triple filing triggers dispute w/Vertex, but diverse deals like $525M frexalimab MS royalty support HSD% long-term growth. Narrow moat from 12yr avg royalty duration on market-leading drugs. Unique ability to structure large, complex deals a competitive edge. M-rated risk from govts but mitigated by diversification. Exemplary stewardship: Strong B/S, exceptional investments, appropriate distributions.
Read full article (9 min)